Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. Show more
Location: 100 Overlook Center, Princeton, NJ, 08540, United States | Website: https://www.sonnetbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
16.37M
52 Wk Range
$1.08 - $10.02
Previous Close
$5.28
Open
$5.40
Volume
638,017
Day Range
$4.86 - $5.67
Enterprise Value
1.957M
Cash
2.059M
Avg Qtr Burn
-2.905M
Insider Ownership
1.53%
Institutional Own.
5.24%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SON-080 Details Chemotherapy-Induced Peripheral Neuropathy & Diabetic Peripheral Neuropathy | Phase 2 Initiation | |
SON-1010 (IL12-FHAB) + Atezolizumab Details Platinum-resistant ovarian cancer | Phase 1/2 Update | |
SON-1210 w/ chemotherapeutic agents Details Advanced Solid Tumors & Pancreatic cancer | Phase 1/2 Initiation | |
SON-1010 (IL12-FHAB) +/- Trabectedin Details Leiomyosarcoma (LMS) or liposarcoma (LPS) | Phase 1 Data readout |